NEW YORK (GenomeWeb News) – German genetic engineering company Gene Bridges said today that it has licensed its DNA recombination technology to Japanese pharmaceutical firm Daiichi Sankyo.

The company said that the technology, which is patented in Japan as a "Novel DNA Cloning Method," is used to generate targeting vectors or for modifying E. coli chromosomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Nov
14
Sponsored by
PerkinElmer

In these times of economic constraint and increasing research costs, shared resource cores have become a cost-effective and essential platform for researchers who seek to investigate complex translational research questions.